Meyers DE - Search Results

1

Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.

Jenei K, Meyers DE. Jenei K, et al. Among authors: meyers de. BMJ Open. 2023 Oct 16;13(10):e066378. doi: 10.1136/bmjopen-2022-066378. BMJ Open. 2023. PMID: 37844982 Free PMC article.

2

Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.

Meyers DE, Jenei K, Chisamore TM, Gyawali B. Meyers DE, et al. JAMA Intern Med. 2021 Apr 1;181(4):499-508. doi: 10.1001/jamainternmed.2020.8588. JAMA Intern Med. 2021. PMID: 33616606 Free PMC article.

3

The Inclusion of Women in Global Oncology Drug Trials Over the Past 20 Years.

Jenei K, Meyers DE, Prasad V. Jenei K, et al. Among authors: meyers de. JAMA Oncol. 2021 Oct 1;7(10):1569-1570. doi: 10.1001/jamaoncol.2021.3686. JAMA Oncol. 2021. PMID: 34436541 Free PMC article.

4

Use of Participation to Prevalence Ratio for Evaluating the Representation Status of Women in Oncology Clinical Trials-Reply.

Jenei K, Meyers DE, Prasad V. Jenei K, et al. Among authors: meyers de. JAMA Oncol. 2022 Mar 1;8(3):480. doi: 10.1001/jamaoncol.2021.6971. JAMA Oncol. 2022. PMID: 34989805 No abstract available.

5

Challenges with sex-specific subgroup analyses in oncology clinical trials for drug approvals between 2015-2020.

Jenei K, Raymakers A, Meyers DE, Prasad V. Jenei K, et al. Among authors: meyers de. J Cancer Policy. 2021 Dec;30:100311. doi: 10.1016/j.jcpo.2021.100311. Epub 2021 Oct 29. J Cancer Policy. 2021. PMID: 35559802

6

Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020.

Jenei K, Meyers D, Gyawali B. Jenei K, et al. JAMA Netw Open. 2023 Jan 3;6(1):e2253438. doi: 10.1001/jamanetworkopen.2022.53438. JAMA Netw Open. 2023. PMID: 36719684 Free PMC article.

7

Cook S, Samuel V, Meyers DE, Stukalin I, Litt I, Sangha R, Morris DG, Heng DYC, Pabani A, Dean M, Navani V. Cook S, et al. Among authors: meyers de. JAMA Netw Open. 2024 Jan 2;7(1):e2352302. doi: 10.1001/jamanetworkopen.2023.52302. JAMA Netw Open. 2024. PMID: 38236598 Free PMC article.

8

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors.

Meyers DE, Pasternak M, Dolter S, Grosjean HAI, Lim CA, Stukalin I, Goutam S, Navani V, Heng DYC, Cheung WY, Morris DG, Pabani A. Meyers DE, et al. JTO Clin Res Rep. 2023 Feb 24;4(4):100482. doi: 10.1016/j.jtocrr.2023.100482. eCollection 2023 Apr. JTO Clin Res Rep. 2023. PMID: 37090101 Free PMC article.

9

Durvalumab-Associated Pneumonitis in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Real-World Population Study.

Lim CA, Ghosh S, Morrison H, Meyers D, Stukalin I, Kerba M, Hao D, Pabani A. Lim CA, et al. Curr Oncol. 2023 Dec 9;30(12):10396-10407. doi: 10.3390/curroncol30120757. Curr Oncol. 2023. PMID: 38132391 Free PMC article.

10

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.

Watson AS, Goutam S, Stukalin I, Ewanchuk BW, Sander M, Meyers DE, Pabani A, Cheung WY, Heng DYC, Cheng T, Monzon JG, Navani V. Watson AS, et al. Among authors: meyers de. JAMA Netw Open. 2022 Dec 1;5(12):e2245596. doi: 10.1001/jamanetworkopen.2022.45596. JAMA Netw Open. 2022. PMID: 36480204 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

70 results

Search Page